Skip to content
Open access · CC-BY via OpenAlex

Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers

Marta Cuadros, Carlos Cano, Sonia García‐Rodríguez, José Luis Díez-Martín, Antonio Poyatos-Andújar, Francisco Ruiz‐Cabello, Susana Pedrinaci, Gema Durán, Manuel Benavides, María Dolores Bautista-Ojeda, Teresa Pereda, Maria S. Benitez‐Cantos, Pedro P. Medina, Armando J. Blanco, Antonio Gustavo González

BMC Medical Genomics · 2022 · ▲ 1 citations

Abstract

BACKGROUND: DNA methylation (DNAm) age metrics have been widely accepted as an epigenetic biomarker for biological aging and disease. The purpose of this study is to assess whether or not individuals carrying Lynch Syndrome-associated mutations are affected in their rate of biological aging, as measured by the epigenetic clock(definition). METHODS: Genome-wide bisulfite DNA sequencing data were generated using DNA from CD4 + T-cells obtained from peripheral blood using 27 patient samples from Lynch syndrome families. Horvath's DNAm age model based on penalized linear regression was applied to estimate DNAm age from patient samples with distinct clinical and genetic characteristics to investigate cancer mutation-related aging effects. RESULTS: Both Lynch mutation carriers and controls exhibited high variability in their estimated DNAm age, but regression analysis showed steeper slope for the Lynch mutation carriers. Remarkably, six Lynch Syndrome-associated mutation carriers showed a strong correlation to the control group, and two sisters carrying Lynch Syndrome-associated mutations, with no significant difference in lifestyle and similar chronological age, were assigned very different DNAm age. CONCLUSIONS: Future studies will be required to explore, in larger patient populations, whether specific epigenetic age acceleration is predictive of time-to-cancer development, treatment response, and survival. Epigenetic clock DNAm metrics may be affected by the presence of cancer mutations in the germline, and thus show promise of potential clinical utility for stratified surveillance strategies based on the relative risk for imminent emergence of tumor lesions in otherwise healthy Lynch Syndrome-associated mutation carriers.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1186/s12920-022-01183-2
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Cuadros, M., Cano, C., García‐Rodríguez, S., Díez-Martín, J.L., Poyatos-Andújar, A., Ruiz‐Cabello, F., Pedrinaci, S., Durán, G., Benavides, M., Bautista-Ojeda, M.D., Pereda, T., Benitez‐Cantos, M.S., Medina, P.P., Blanco, A.J., González, A.G., &amp; Lizardi, P.M. (2022). Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers. <em>BMC Medical Genomics</em>. https://doi.org/10.1186/s12920-022-01183-2
Vancouver
Cuadros M, Cano C, García‐Rodríguez S, Díez-Martín JL, Poyatos-Andújar A, Ruiz‐Cabello F, et al. Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers. BMC Medical Genomics. 2022. doi:10.1186/s12920-022-01183-2.
BibTeX
@article{marta2022Accele, title = {Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers}, author = {Marta Cuadros and Carlos Cano and Sonia García‐Rodríguez and José Luis Díez-Martín and Antonio Poyatos-Andújar and Francisco Ruiz‐Cabello and Susana Pedrinaci and Gema Durán and Manuel Benavides and María Dolores Bautista-Ojeda and Teresa Pereda and Maria S. Benitez‐Cantos and Pedro P. Medina and Armando J. Blanco and Antonio Gustavo González and Paul M. Lizardi}, journal = {BMC Medical Genomics}, year = {2022}, doi = {10.1186/s12920-022-01183-2}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings